Outcomes of Anxiety and Depression in Medical Cannabis Patients
Toronto, Ontario–(Newsfile Corp. – June 3, 2022) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“LIVE“or the”Company“), a leading provider of medical cannabis products and patient services, and licensee under the Cannabis law through its wholly-owned subsidiaries, Canna Farms Limited (“Canna Farms”), ABcann Medicinals Inc., today announced the results of its first study investigating the impact of medical cannabis on anxiety and the Depression. The publication, titled “Medical cannabis use in Canada and its impact on anxiety and depression: a retrospective study” was published in the peer-reviewed journal Psychiatric research and was made by VIVO’s Harvest Medicine Inc (“HMED”) subsidiary. To the Company’s knowledge, this is the largest study of its kind to date, examining the impact of medical cannabis using longitudinal data and completed validated questionnaires for anxiety (GAD-7 ) and depression (PHQ-9) in 7,362 Canadian patients. The analyzes were conducted over three different periods: 3 to 6 months, 12 to 18 months and 24 months or more.
The study was led by the HMED team of prescribing clinicians and physician support staff. Patients using medical cannabis for anxiety and/or depression saw statistically significant improved results between baseline and follow-up scores. This study provides evidence supporting the effectiveness of medical cannabis as a treatment for anxiety and depression.
“Since 2017, Harvest Medicine has been a network of high-volume, industry-leading cannabis clinics, and our team has worked hard to share this clinical information with the goal of contributing to the medical cannabis literature and reduce stigma among healthcare professionals,” said Carole Chan, RPh, president of Harvest Medicine. “We are committed to continuing research and advancing patient outcomes through an evidence-based approach to patient care.”
About VIVO Cannabis
VIVO Cannabis® is recognized for its premium and reliable cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licenses from Health Canada and operates world-class indoor cultivation facilities. VIVO offers a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™ and Lumina™. Harvest Medicine™, VIVO’s scalable, patient-centric network of medical cannabis clinics, has served over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com
For more information:
VIVO Investor Relations
Michael Bumby, Chief Financial Officer
Disclaimer Regarding Forward-Looking Information
Certain statements in this press release are forward-looking statements, which are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. These statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will derive therefrom. Readers are urged to carefully consider these factors as well as the broader risk factors included in the Company’s most recent MD&A available on SEDAR when evaluating the forward-looking statements contained in this press release and are cautioned not to place undue reliance on these forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company disclaims any intention or obligation to publicly update such forward-looking statements, whether as a result of new information, future events or results. or otherwise, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/126374